A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia - PubMed (original) (raw)
Comparative Study
doi: 10.1002/ana.21321.
Tetsu Nagata, Hiroyuki Shimada, Rie Teraoka, Akiko Fukushima, Hyoue Kanemitsu, Hiroshi Takuma, Ryozo Kuwano, Masaki Imagawa, Suzuka Ataka, Yasuhiro Wada, Eito Yoshioka, Tomoyuki Nishizaki, Yasuyoshi Watanabe, Hiroshi Mori
Affiliations
- PMID: 18300294
- DOI: 10.1002/ana.21321
Comparative Study
A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia
Takami Tomiyama et al. Ann Neurol. 2008 Mar.
Abstract
Objective: Soluble oligomers of amyloid beta (Abeta), rather than amyloid fibrils, have been proposed to initiate synaptic and cognitive dysfunction in Alzheimer's disease (AD). However, there is no direct evidence in humans that this mechanism can cause AD. Here, we report a novel amyloid precursor protein (APP) mutation that may provide evidence to address this question.
Methods: A Japanese pedigree showing Alzheimer's-type dementia was examined for mutations in APP, PSEN1, and PSEN2. In addition, 5,310 Japanese people, including 2,121 patients with AD, were screened for the novel APP mutation. The pathogenic effects of this mutation on Abeta production, degradation, aggregation, and synaptotoxicity were also investigated.
Results: We identified a novel APP mutation (E693Delta) producing variant Abeta lacking gulutamate-22 (E22Delta) in Japanese pedigrees showing Alzheimer's-type dementia and AD. Although the secretion of total Abeta was markedly reduced by this mutation, the variant Abeta was more resistant to proteolytic degradation. The mutant peptides showed the unique aggregation property of enhanced oligomerization but no fibrillization, and inhibited hippocampal long-term potentiation more potently than wild-type peptide in rats in vivo. Consistent with the nonfibrillogenic property of the variant Abeta, a very low amyloid signal was observed in the patient's brain on positron emission tomography using Pittsburgh compound-B.
Interpretation: The E693Delta mutation has been suggested as a cause of dementia because of enhanced formation of synaptotoxic Abeta oligomers. Our findings may provide genetic validation in humans for the emerging hypothesis that the synaptic and cognitive impairment in AD is primarily caused by soluble Abeta oligomers.
Similar articles
- Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.
Kulic L, McAfoose J, Welt T, Tackenberg C, Späni C, Wirth F, Finder V, Konietzko U, Giese M, Eckert A, Noriaki K, Shimizu T, Murakami K, Irie K, Rasool S, Glabe C, Hock C, Nitsch RM. Kulic L, et al. Transl Psychiatry. 2012 Nov 13;2(11):e183. doi: 10.1038/tp.2012.109. Transl Psychiatry. 2012. PMID: 23149447 Free PMC article. - APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance.
Tomiyama T, Shimada H. Tomiyama T, et al. Int J Mol Sci. 2020 Feb 19;21(4):1413. doi: 10.3390/ijms21041413. Int J Mol Sci. 2020. PMID: 32093100 Free PMC article. Review. - Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
Tackenberg C, Kulic L, Nitsch RM. Tackenberg C, et al. PLoS One. 2020 Sep 23;15(9):e0239584. doi: 10.1371/journal.pone.0239584. eCollection 2020. PLoS One. 2020. PMID: 32966331 Free PMC article. - Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.
Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK. Poduslo JF, et al. Biochemistry. 2012 May 15;51(19):3993-4003. doi: 10.1021/bi300275g. Epub 2012 May 7. Biochemistry. 2012. PMID: 22545812 - Alzheimer's disease.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
Cited by
- Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.
Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Cohen AD, et al. Adv Pharmacol. 2012;64:27-81. doi: 10.1016/B978-0-12-394816-8.00002-7. Adv Pharmacol. 2012. PMID: 22840744 Free PMC article. Review. - The structures of the E22Δ mutant-type amyloid-β alloforms and the impact of E22Δ mutation on the structures of the wild-type amyloid-β alloforms.
Coskuner O, Wise-Scira O, Perry G, Kitahara T. Coskuner O, et al. ACS Chem Neurosci. 2013 Feb 20;4(2):310-20. doi: 10.1021/cn300149j. Epub 2012 Dec 18. ACS Chem Neurosci. 2013. PMID: 23421682 Free PMC article. - Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta.
Akbor MM, Kurosawa N, Nakayama H, Nakatani A, Tomobe K, Chiba Y, Ueno M, Tanaka M, Nomura Y, Isobe M. Akbor MM, et al. PLoS One. 2021 Mar 4;16(3):e0248027. doi: 10.1371/journal.pone.0248027. eCollection 2021. PLoS One. 2021. PMID: 33662018 Free PMC article. - Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases.
Krishnadas N, Doré V, Laws SM, Porter T, Lamb F, Bozinovski S, Villemagne VL, Rowe CC. Krishnadas N, et al. Alzheimers Dement (Amst). 2022 Aug 26;14(1):e12326. doi: 10.1002/dad2.12326. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36051174 Free PMC article. - Alzheimer's disease: synaptic dysfunction and Abeta.
Shankar GM, Walsh DM. Shankar GM, et al. Mol Neurodegener. 2009 Nov 23;4:48. doi: 10.1186/1750-1326-4-48. Mol Neurodegener. 2009. PMID: 19930651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical